These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 37886955)

  • 1. Targeting GD2-Positive Tumor Cells by Pegylated scFv Fragment-Drug Conjugates Carrying Maytansinoids DM1 and DM4.
    Kalinovsky DV; Kholodenko IV; Svirshchevskaya EV; Kibardin AV; Ryazantsev DY; Rozov FN; Larin SS; Deyev SM; Kholodenko RV
    Curr Issues Mol Biol; 2023 Oct; 45(10):8112-8125. PubMed ID: 37886955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multimerization through Pegylation Improves Pharmacokinetic Properties of scFv Fragments of GD2-Specific Antibodies.
    V Kholodenko I; V Kalinovsky D; V Svirshchevskaya E; I Doronin I; V Konovalova M; V Kibardin A; V Shamanskaya T; S Larin S; M Deyev S; V Kholodenko R
    Molecules; 2019 Oct; 24(21):. PubMed ID: 31653037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Minibody-Based and scFv-Based Antibody Fragment-Drug Conjugates Selectively Eliminate GD2-Positive Tumor Cells.
    Kalinovsky DV; Kholodenko IV; Kibardin AV; Doronin II; Svirshchevskaya EV; Ryazantsev DY; Konovalova MV; Rozov FN; Larin SS; Deyev SM; Kholodenko RV
    Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic efficacy of antibody-drug conjugates targeting GD2-positive tumors.
    Kalinovsky DV; Kibardin AV; Kholodenko IV; Svirshchevskaya EV; Doronin II; Konovalova MV; Grechikhina MV; Rozov FN; Larin SS; Deyev SM; Kholodenko RV
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35764367
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of site-specific ScFv PEGylation for tumor-targeting pharmaceuticals.
    Natarajan A; Xiong CY; Albrecht H; DeNardo GL; DeNardo SJ
    Bioconjug Chem; 2005; 16(1):113-21. PubMed ID: 15656582
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates.
    Erickson HK; Widdison WC; Mayo MF; Whiteman K; Audette C; Wilhelm SD; Singh R
    Bioconjug Chem; 2010 Jan; 21(1):84-92. PubMed ID: 19891424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PEGylation and multimerization of the anti-p185HER-2 single chain Fv fragment 4D5: effects on tumor targeting.
    Kubetzko S; Balic E; Waibel R; Zangemeister-Wittke U; Plückthun A
    J Biol Chem; 2006 Nov; 281(46):35186-201. PubMed ID: 16963450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chimeric single-chain variable fragment-human immunoglobulin G crystallizable fragment antibody against GD2 for neuroblastoma targeted immunotherapy.
    Laopajon W; Takheaw N; Kotemul K; Pata S; Hongeng S; Kasinrerk W
    Explor Target Antitumor Ther; 2023; 4(6):1145-1156. PubMed ID: 38213540
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful engineering of a highly potent single-chain variable-fragment (scFv) bispecific antibody to target disialoganglioside (GD2) positive tumors.
    Cheng M; Santich BH; Xu H; Ahmed M; Huse M; Cheung NK
    Oncoimmunology; 2016 Jun; 5(6):e1168557. PubMed ID: 27471647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Engineered scPDL1-DM1 drug conjugate with improved in vitro analysis to target PD-L1 positive cancer cells and intracellular trafficking studies in cancer therapy.
    Kalim M; Wang S; Liang K; Khan MSI; Zhan J
    Genet Mol Biol; 2020; 42(4):e20180391. PubMed ID: 31967634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Generation and characterization of a mouse single-chain antibody fragment specific for disialoganglioside (GD2).
    Moutel S; Birkle S; Laurence V; Michon J; Fridman WH; Aubry J; Teillaud JL
    Hybridoma; 1997 Aug; 16(4):335-46. PubMed ID: 9309424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of tumor targeting anti-MUC-1 multimer: effects of di-scFv unpaired cysteine location on PEGylation and tumor binding.
    Xiong CY; Natarajan A; Shi XB; Denardo GL; Denardo SJ
    Protein Eng Des Sel; 2006 Aug; 19(8):359-67. PubMed ID: 16760193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapid Evaluation of Antibody Fragment Endocytosis for Antibody Fragment-Drug Conjugates.
    Kim EG; Jeong J; Lee J; Jung H; Kim M; Zhao Y; Yi EC; Kim KM
    Biomolecules; 2020 Jun; 10(6):. PubMed ID: 32630402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ganglioside GD2-specific trifunctional surrogate antibody Surek demonstrates therapeutic activity in a mouse melanoma model.
    Ruf P; Schäfer B; Eissler N; Mocikat R; Hess J; Plöscher M; Wosch S; Suckstorff I; Zehetmeier C; Lindhofer H
    J Transl Med; 2012 Nov; 10():219. PubMed ID: 23134699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting both GD2 and B7-H3 using bispecific antibody improves tumor selectivity for GD2-positive tumors.
    Rosenkrans ZT; Erbe AK; Clemons NB; Feils AS; Medina-Guevara Y; Jeffery JJ; Barnhart TE; Engle JW; Sondel PM; Hernandez R
    bioRxiv; 2024 May; ():. PubMed ID: 38853889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Understanding How the Stability of the Thiol-Maleimide Linkage Impacts the Pharmacokinetics of Lysine-Linked Antibody-Maytansinoid Conjugates.
    Ponte JF; Sun X; Yoder NC; Fishkin N; Laleau R; Coccia J; Lanieri L; Bogalhas M; Wang L; Wilhelm S; Widdison W; Pinkas J; Keating TA; Chari R; Erickson HK; Lambert JM
    Bioconjug Chem; 2016 Jul; 27(7):1588-98. PubMed ID: 27174129
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polymer Cancerostatics Targeted by Recombinant Antibody Fragments to GD2-Positive Tumor Cells.
    Pola R; Král V; Filippov SK; Kaberov L; Etrych T; Sieglová I; Sedláček J; Fábry M; Pechar M
    Biomacromolecules; 2019 Jan; 20(1):412-421. PubMed ID: 30485077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monospecific bivalent scFv-SH: effects of linker length and location of an engineered cysteine on production, antigen binding activity and free SH accessibility.
    Albrecht H; Denardo GL; Denardo SJ
    J Immunol Methods; 2006 Mar; 310(1-2):100-16. PubMed ID: 16499921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced therapeutic potential of antibody fragment via IEDDA-mediated site-specific albumin conjugation.
    Go EB; Lee JH; Cho JH; Kwon NH; Choi JI; Kwon I
    J Biol Eng; 2024 Apr; 18(1):23. PubMed ID: 38576037
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.